Diabetes

October 6, 2017

Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Luteolin, Apogenin, Formononetin, Isoliquiritigenin , and Gallic acid (LAFIG) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 6/October/2017, 11.51 pm

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
October 5, 2017

Natural product-derived regenerative therapy for reversing diabetes: A pharmaceutical mixture encompassing Celastrol, Mangiferin, Omega-3, Taurine, & Vit-D/C/E (CMOTV-DCE) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 6/October/2017, 1.27 am

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, […]
October 5, 2017

Small molecule-based therapy for TIIDM, Metabolic defects and Longevity: L-deprenyl,  used in the treatment of Parkinson’s disease and depression, increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 06/October/2017, 12.49 am

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC […]
October 3, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Milnacipran, a serotonin norepinephrine reuptake inhibitor,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/October/2017, 2.39 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]